Corpay Cross-Border Named the Global FX Partner of UFC
10.12.2024 14:30:00 CET | Business Wire | Press release
Providing access to currency risk management and cross-border payments solutions
Corpay, Inc.* (NYSE: CPAY), a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with UFC, the world's premier mixed martial arts (MMA) organization, to become their official and exclusive Global Foreign Exchange (FX) Partner.
"UFC has revolutionized the sport of mixed martial arts, and the team at Corpay Cross-Border is excited to be named their exclusive Global FX Partner,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “Being recognized as an official partner of a premium global sports brand such as UFC further solidifies Corpay’s position as the currency risk management and cross-border payments solutions company of choice in the world of sports.”
“We’re thrilled to welcome Corpay as a first-time UFC partner,” said Nicholas Smith, Vice President of Global Partnerships for TKO. “Corpay provides a valuable service to business looking to streamline the way they manage and pay their expenses. We’re confident the worldwide popularity of UFC and the global reach of our platforms will help them reach new customers.”
Branded Entitlements and Activations
As the Official Global FX Partner of UFC, Corpay will serve as the Presenting Partner of select UFC Fight Nights in Asia, Australia, Europe, and the Middle East. In addition, Corpay branding will be integrated into the state-of-the-art LED UFC Fight Deck that encircles the world-famous Octagon,® enhanced with thrilling lighting effects, graphics, animation, video, and more.
Corpay branding will also be featured on the UFC Prep Point, the pivotal location where each UFC athlete undergoes a safety check with commission officials before entering the Octagon to face their opponent.
Beyond the Octagon, Corpay will also have a highly visible presence at popular UFC fight week activities, including press conferences and weigh-ins, that help build anticipation for the main events.
Corpay will first activate the partnership at UFC FIGHT NIGHT Riyadh in Saudi Arabia on Saturday, February 1st at The Venue, Riyadh. With a soon-to-be-announced fight card, the event will see several of the sport’s most talented athletes enter the Octagon® for an action-packed night. The event marks UFC’s second event in Riyadh, following its historic debut earlier this year.
About Corpay
Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments company that helps businesses and consumers pay expenses in a simple, controlled manner. Corpay’s suite of modern payment solutions help its customers better manage vehicle-related expenses (such as fuelling and parking), travel expenses (e.g. hotel bookings) and payables (e.g. paying vendors). This results in our customers saving time and ultimately spending less. Corpay Cross-Border refers to a group of legal entities owned and operated by Corpay, Inc.
Corpay – Payments made easy. To learn more visit www.corpay.com.
About UFC®
UFC® is the world’s premier mixed martial arts organization (MMA), with more than 700 million fans and approximately 290 million social media followers. The organization produces more than 40 live events annually in some of the most prestigious arenas around the world while broadcasting to over 975 million households across more than 170 countries. UFC’s athlete roster features the world’s best MMA athletes representing more than 80 countries. The organization’s digital offerings include UFC FIGHT PASS®, one of the world’s leading streaming services for combat sports. UFC is part of TKO Group Holdings (NYSE: TKO) and is headquartered in Las Vegas, Nevada. For more information, visit UFC.com and follow UFC at Facebook.com/UFC and @UFC on X, Snapchat, Instagram, and TikTok: @UFC.
*“Corpay” in this document primarily refers to the Cross-Border Division of Corpay, Inc. https://www.corpay.com/cross-border; a full listing of the companies that are part of Corpay Cross-Border is available here: https://www.corpay.com/compliance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210453199/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 13:42:00 CEST | Press release
Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bnAcquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditionsTransaction expected to close in Q3 2026 Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202604
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom